Testosterone and metabolic syndrome

Asian Journal of Andrology

Volumn 17, Issue 2, 2015, Pages 192-196

  Cunningham, Glenn R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

cardiovascular risk; metabolic syndrome; sex hormone binding globulin; testosterone; testosterone replacement therapy

Indexed keywords

HEMOGLOBIN A1C; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ANDROGEN THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET; EXERCISE; FOOD AND DRUG ADMINISTRATION; GLUCOSE METABOLISM; HUMAN; HYPERINSULINISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; MALE; METABOLIC SYNDROME X; OBSERVATIONAL STUDY; REVIEW; RISK FACTOR; UNITED STATES; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; ADVERSE EFFECTS; BODY COMPOSITION; CARDIOVASCULAR DISEASES; DEFICIENCY; DRUG EFFECTS; FEMALE; HORMONE SUBSTITUTION; PATHOPHYSIOLOGY; PHYSIOLOGY; TREATMENT OUTCOME;

BODY COMPOSITION; CARDIOVASCULAR DISEASES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; RISK FACTORS; TESTOSTERONE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84924746563     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.148068     Document Type: Review

References (46)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
2. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, et al. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes 2004; 53: 1195-200.
3. Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007; 92: 3568-72.
4. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 2011; 25: 337-53.
5. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011; 8: 272-83.
6. Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PLoS One 2014; 9: e100409.
7. Zhang J, Huang X, Liao M, Gao Y, Tan A, et al. Both total testosterone and sex hormone-binding globulin are independent risk factors for metabolic syndrome: results from Fangchenggang area male health and examination survey in China. Diabetes Metab Res Rev 2013; 29: 391-7.
8. Pang XN, Hu Y, Yuan Y, Shen JP, Zha XY, et al. Lower levels sex hormone-binding globulin independently associated with metabolic syndrome in pre-elderly and elderly men in China. J Geriatr Cardiol 2013; 10: 28-33.
9. Hong D, Kim YS, Son ES, Kim KN, Kim BT, et al. Total testosterone and sex hormone-binding globulin are associated with metabolic syndrome independent of age and body mass index in Korean men. Maturitas 2013; 74: 148-53.
10. Hautanen A. Synthesis and regulation of sex hormone-binding globulin in obesity. Int J Obes Relat Metab Disord 2000; 24 Suppl 2: S64-70.
11. Pasquali R, Casimirri F, De Iasio R, Mesini P, Boschi S, et al. Insulin regulates testosterone and sex hormone-binding globulin concentrations in adult normal weight and obese men. J Clin Endocrinol Metab 1995; 80: 654-8.
12. Maggio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, et al. Estradiol and metabolic syndrome in older italian men: the InCHIANTI study. J Androl 2010; 31: 155-62.
13. Santen RJ. Is aromatization of testosterone to estradiol required for inhibition of luteinizing hormone secretion in men? J Clin Invest 1975; 56: 1555-63.
14. Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res 2003; 15: 156-65.
15. Herman AP, Krawczynska A, Bochenek J, Dobek E, Herman A, et al. LPS-induced inflammation potentiates the IL-1β-mediated reduction of LH secretion from the anterior pituitary explants. Clin Dev Immunol 2013; 2013: 926937.
16. Bornstein SR, Rutkowski H, Vrezas I. Cytokines and steroidogenesis. Mol Cell Endocrinol 2004; 215: 135-41.
17. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, et al . Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843-50.
18. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004; 27: 1036-41.
19. Bhasin S, Jasjua GK, Pencina M, D'Agostino R Sr, Coviello AD, et al. Sex hormone-binding globulin, but not testosterone, is associated prospectively and independently with incident metabolic syndrome in men: the framingham heart study. Diabetes Care 2011; 34: 2464-70.
20. Hsu B, Cumming RG, Naganathan V, Blyth FM, Le Couteur DG, et al. Associations between circulating reproductive hormones and SHBG and prevalent and incident metabolic syndrome in community-dwelling older men: the Concord health and ageing in men project. J Clin Endocrinol Metab 2014; 99: E2686-91.
21. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006; 24: 3979-83.
22. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2013; 189: S34-42.
23. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75.
24. Lin JW, Lee JK, Wu CK, Caffrey JL, Chang MH, et al. Metabolic syndrome, testosterone, and cardiovascular mortality in men. J Sex Med 2011; 8: 2350-60.
25. Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 2011; 97: 870-5.
26. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-19.
27. Muraleedharan V, Jones TH. Testosterone and mortality. Clin Endocrinol (Oxf) 2014; 81: 477-87.
28. Marin P, Holmang S, Gustafsson C, Jonsson L, Kvist H, et al. Androgen treatment of abdominally obese men. Obes Res 1993; 1: 245-51.
29. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
30. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828-37.
31. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med 2014; 11: 840-56.
32. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30: 726-33.
33. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012; 167: 531-41.
34. Cai X, Tian Y, Wu T, Cao CX, Li H, et al. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl 2014; 16: 146-52.
35. Gianatti EJ, Dupuis P, Hoermann R, Strauss BJ, Wentworth JM, et al. Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. Diabetes Care 2014; 37: 2098-107.
36. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014; 2014: 683515.
37. Traish AM. Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes 2014; 21: 313-22.
38. Høst C, Gormsen LC, Hougaard DM, Christiansen JS, Pedersen SB, et al. Acute and short-term chronic testosterone fluctuation effects on glucose homeostasis, insulin sensitivity, and adiponectin: a randomized, double-blind, placebo-controlled, crossover study. J Clin Endocrinol Metab 2014; 99: E1088-96.
39. Pitteloud N, Mootha VK, Dwyer AA, Hardin M, Lee H, et al. Relationship between testosterone levels, insulin sensitivity, and mitochondrial function in men. Diabetes Care 2005; 28: 1636-42.
40. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73: 602-12.
41. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol 2014; 2014: 527470.
42. Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med 2014; 11: 1567-76.
43. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 2014; 68: 314-29.
44. Bhattacharya RK, Khera M, Blick G, Kushner H, Nguyen D, et al. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord 2011; 11: 18.
45. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.
46. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf 2014; 13: 1327-51.